Skip to main content

Table 1 Characteristics of the studies (RCTs) included in the meta-analysis

From: The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis

First author (year)Study typeCountriesAverage follow-up periodPatient characteristicsNumber of cases/number of patientsNumber of cases/number of patients
    Age (years)Number of sexual partners  
    Vaccinated groupaPlacebo groupb  Vaccinated groupPlacebo group
Garland (2007) [20]RCT16 countries from Asia Pacific, Europe, North- Central- and South America3 years20.2 ± 1.820.3 ± 1.816–24< 40/226148/2279
Dillner (2010) [21]RCT24 countries from North America, Latin America, Europe, Asia Pacific42 months2016–26< 42/6718186/6647
Majewski (2009) [22]RCTAustria, Czech Republic, Denmark, England, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Norway, Poland, Portugal, Russian Federation, Spain, and Sweden.36 months19.716–24≤41/405990/4057
Villa (2006)
RCTBrazil, Nordic countries, Finland, Sweden, Norway60 months20.220.016–23≤40/21420/209
Munoz (2010) [24]RCTAustralia, Austria, Brazil, Canada, Colombia, Czech Republic, Denmark, Finland, Germany, Hong Kong, Iceland, Italy, Mexico, New Zealand, Norway, Peru, Poland, Puerto Rico, Russia, Singapore, Sweden, Thailand, the United Kingdom, United States3,6 years??15–26< 4 except Finnish women4/4689138/4735
Perez (2008) [25]RCTBrazil, Mexico, Colombia, Costa Rica, Guatemala, Peru?19.8 ± 3.020.3 ± 2.29–24≤40/20759/1976
Yoshikawa (2013) [26]RCTJapan23 months22.7 ± 2.122.9 ± 2.118–26≤42/4007/376
Mikamo (2019) [16]RCTJapan36 months22.6 ± 2.122.6 ± 2.018–2717–260/5611/562
  1. RCT: randomised controlled trial
  2. a: vaccine = quadrivalent HPV vaccine (HPV types 6, 11, 16, 18)
  3. b: placebo = aluminium hydroxyphosphate sulphate adjuvant